Madrid

• A study to learn if dapirolizumab pegol works and is safe in people with moderately to severely active systemic lupus erythematosus (SLE) Recruiting
  2023-508191-11-00 5 2024-11-28 Systemic lupus erythematosus (SLE)
• A Phase 1 Study of BMS-986453 in Participants with Relapsed and/or Refractory Multiple Myeloma Recruiting
  2023-506003-26-00 1 2024-11-27 Relapsed and/or Refractory Multiple Myeloma
• A Phase 2, open label, randomized study of neoadjuvant dostarlimab plus CAPEOX versus CAPEOX in participants with previously untreated T4N0 … Recruiting
  2024-513441-36-00 4 2024-11-27 MMRp/ MSS colon cancer
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting
  2024-512279-10-00 5 2024-11-25 Triple Negative Breast Cancer
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensate … Recruiting
  2024-512895-36-00 5 2024-11-25 Metabolic Dysfunction-Associated Steatohepatitis (MASH)
• Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308) Recruiting
  2024-511838-12-00 3 2024-11-22 Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
• Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting
  2024-513009-30-00 4 2024-11-21 Moderate to Severe Crohn’s Disease
• A Study of ZL-1310 in Patients with Small Cell Lung Cancer to Find a Suitable Dose and to Test How Different Doses of ZL-1310 are Tolerated … Recruiting
  2024-514446-36-00 1 2024-11-21 Small Cell Lung Cancer
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• Use of statins in patients with intracerebral hemorrhage Recruiting
  2024-511465-11-00 5 2024-11-20 Spontaneous lobar ICH
• An open-label study to assess reduction of daily asthma medication with tezepelumab in patients 12 to 80 years of age with severe asthma Recruiting
  2024-512113-41-00 5 2024-11-20 Severe Asthma
• LATE-R trial. A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients with Lat … Recruiting
  2024-512835-53-00 4 2024-11-20 Diffuse Large B-Cell Lymphoma
• Randomised, double-blind, multicentre, phase III clinical trial to evaluate the efficacy and safety of dexamethasone compared to placebo in … Recruiting
  2024-513209-30-00 5 2024-11-20 Severe Influenza
• A Phase IV, Multicenter, Open-label, Single-arm Study to Evaluate the Safety of Almagate in Pregnant Women With Heartburn and Reflux, and Pe … Recruiting
  2024-515381-14-00 6 2024-11-20 heartburn and or reflux
• Effect of dual bronchodilation with umeclidinium/vilanterol on patients with COPD, hyperinflation and heart failure Recruiting
  2024-519513-61-00 6 2024-11-20 Chronic obstructive pulmonary diseases with Heart Failure with eyectio
• Continuing Anticoagulants and Antiplatelets in Cold snare Polypectomy. Recruiting
  2024-511265-11-01 6 2024-11-19 patients who are requested a colonoscopy for any indication and are un
• Bomedemstat vs Hydroxyurea for Essential Thrombocythemia Recruiting
  2023-505232-36-00 5 2024-11-15 Essential thrombocythemia
• MK-1084 with Pembrolizumab in 1L Locally Advanced or Metastatic NSCLC With KRAS G12C Mutations and PD-L1 ≥50% Recruiting
  2023-507776-42-00 5 2024-11-14 Non-small cell lung cancer
• A first-in-human study of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors. Recruiting
  2023-509230-19-00 7 2024-11-14 Advance solid tumors
• Study of MEN1703 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Recruiting
  2024-513098-31-00 4 2024-11-14 Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
• General anesthesia versus sedation with high-flow nasal cannula for the endovascular treatment of acute ischemic stroke Recruiting
  2024-510752-12-00 6 2024-11-13 Acute ischemic stroke
• Letermovir (LMV) prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients with CMV seropositive donors Recruiting
  2024-516011-24-01 4 2024-11-13 Cytomegalovirus infection in allogeneic stem cell transplant recipient
• A study of AZD0901 alone or in combination with other anticancer drugs in patients with advanced/metastatic cancer. Recruiting
  2023-508275-37-00 9 2024-11-11 Gastric Cancer, Gastroesophageal Junction Cancer, Pancreatic Ductal Ad
• A Phase I, open-label, multi-center study of radiation dosimetry, safety, and tolerability of extended lutetium (177Lu) vipivotide tetraxeta … Recruiting
  2024-512338-13-00 3 2024-11-11 Metastatic Castration-Resistant Prostate Cancer

Showing 1,225–1,248 of 3,550 trials